These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 1966973)

  • 1. Metalloporphyrin magnetic resonance contrast agents. Feasibility of tumor-specific magnetic resonance imaging.
    van Zijl PC; Place DA; Cohen JS; Faustino PJ; Lyon RC; Patronas NJ
    Acta Radiol Suppl; 1990; 374():75-9. PubMed ID: 1966973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metalloporphyrin contrast agents for magnetic resonance imaging of human tumors in mice.
    Patronas NJ; Cohen JS; Knop RH; Dwyer AJ; Colcher D; Lundy J; Mornex F; Hambright P; Sohn M; Myers CE
    Cancer Treat Rep; 1986 Mar; 70(3):391-5. PubMed ID: 3955550
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Specific and non-specific contrast media for MRI of tumors. Experimental study of human breast carcinoma].
    Revel D; Ogan M; Paajanen H; Grodd W; Couet W; Rosenau W; Brasch RC
    J Radiol; 1989 Feb; 70(2):115-21. PubMed ID: 2715972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI contrast-dose relationship of manganese(III)tetra(4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T.
    Place DA; Faustino PJ; Berghmans KK; van Zijl PC; Chesnick AS; Cohen JS
    Magn Reson Imaging; 1992; 10(6):919-28. PubMed ID: 1461089
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue distribution and stability of metalloporphyrin MRI contrast agents.
    Lyon RC; Faustino PJ; Cohen JS; Katz A; Mornex F; Colcher D; Baglin C; Koenig SH; Hambright P
    Magn Reson Med; 1987 Jan; 4(1):24-33. PubMed ID: 3821476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice.
    Furmanski P; Longley C
    Cancer Res; 1988 Aug; 48(16):4604-10. PubMed ID: 3396012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metalloporphyrins as contrast agents for tumors in magnetic resonance imaging.
    Place DA; Faustino PJ; van Zijl PC; Chesnick A; Cohen JS
    Invest Radiol; 1990 Sep; 25 Suppl 1():S69-70. PubMed ID: 2283262
    [No Abstract]   [Full Text] [Related]  

  • 8. Mn-porphyrins as novel molecular magnetic resonance imaging contrast agents.
    Mouraviev V; Venkatraman TN; Tovmasyan A; Kimura M; Tsivian M; Mouravieva V; Polascik TJ; Wang H; Amrhein TJ; Batinic-Haberle I; Lascola C
    J Endourol; 2011 Nov; ():1420-4. PubMed ID: 22050509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy.
    Liang X; Li X; Jing L; Yue X; Dai Z
    Biomaterials; 2014 Aug; 35(24):6379-88. PubMed ID: 24818886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-enhanced MRI with new biodegradable macromolecular Gd(III) complexes in tumor-bearing mice.
    Zong Y; Wang X; Goodrich KC; Mohs AM; Parker DL; Lu ZR
    Magn Reson Med; 2005 Apr; 53(4):835-42. PubMed ID: 15799038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging. A study of human carcinoma, lymphoma, and fibrosarcoma in mice.
    Ogan MD; Revel D; Brasch RC
    Invest Radiol; 1987 Oct; 22(10):822-8. PubMed ID: 3429177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complementary strategies for developing Gd-free high-field T₁ MRI contrast agents based on Mn(III) porphyrins.
    Cheng W; Haedicke IE; Nofiele J; Martinez F; Beera K; Scholl TJ; Cheng HL; Zhang XA
    J Med Chem; 2014 Jan; 57(2):516-20. PubMed ID: 24328058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contrast-enhanced high resolution magnetic resonance imaging of pigmented malignant melanoma using Mn-TPPS4 and Gd-DTPA: experimental results.
    Mäurer J; Strauss A; Ebert W; Bauer H; Felix R
    Melanoma Res; 2000 Feb; 10(1):40-6. PubMed ID: 10711639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor-selective contrast enhancing agent, Mn(III)meso- [tri(4-sulfonatophenyl)phenyl]porphine (MnTPPS3).
    Fiel R; Mark E; Button T; Gilani S; Musser D
    Magn Reson Imaging; 1993; 11(7):1079-81. PubMed ID: 8231675
    [No Abstract]   [Full Text] [Related]  

  • 15. Contrast enhancement of PC-3 prostate cancer for magnetic resonance imaging: animal studies using tumor-localizing Mn-metalloporphyrin (THF-Mn-Asp).
    Suzuki T; Nakano K; Tomiyoshi K; Sakata I; Endo K; Yamanaka H
    J Urol; 1996 Nov; 156(5):1850-2. PubMed ID: 8863630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging.
    Wilmes LJ; Pallavicini MG; Fleming LM; Gibbs J; Wang D; Li KL; Partridge SC; Henry RG; Shalinsky DR; Hu-Lowe D; Park JW; McShane TM; Lu Y; Brasch RC; Hylton NM
    Magn Reson Imaging; 2007 Apr; 25(3):319-27. PubMed ID: 17371720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
    Caravan P
    Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mn porphyrins as novel molecular magnetic resonance imaging contrast agents.
    Mouraviev V; Venkatraman TN; Tovmasyan A; Kimura M; Tsivian M; Mouravieva V; Polascik TJ; Wang H; Amrhein TJ; Batinic-Haberle I; Lascola C
    J Endourol; 2012 Nov; 26(11):1420-4. PubMed ID: 22783812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamic micro-magnetic resonance imaging of liver micrometastasis in mice with a novel liver macromolecular magnetic resonance contrast agent DAB-Am64-(1B4M-Gd)(64).
    Kobayashi H; Saga T; Kawamoto S; Sato N; Hiraga A; Ishimori T; Konishi J; Togashi K; Brechbiel MW
    Cancer Res; 2001 Jul; 61(13):4966-70. PubMed ID: 11431325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DCE-MRI using small-molecular and albumin-binding contrast agents in experimental carcinomas with different stromal content.
    Farace P; Merigo F; Fiorini S; Nicolato E; Tambalo S; Daducci A; Degrassi A; Sbarbati A; Rubello D; Marzola P
    Eur J Radiol; 2011 Apr; 78(1):52-9. PubMed ID: 19443159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.